BCHE and myalgic encephalomeyelitis/chronic fatigue syndrome: Butyrylcholinesterase inhibition was estimated to be 95.3% for rivastigmine and 84.6% for CFS (Fig. 4), while amylase inhibition of the medication (acarbose) and CFS was 97.6% & 94.2%, respectively (Fig. 5).